Science Advances· 2026Q1
A Full-Spectrum Generative Lead Discovery (FSGLD) pipeline via DRUG-GAN: A multiscale method for drug-like/target-specific compound library generation
- 2citations
- Q1SCImago
- 2026year
Short summary
A new deep learning pipeline, FSGLD, integrates generative modeling (DRUG-GAN) with multiscale simulations and validation to discover drug-like and target-specific compounds, reducing lead identification costs.
AI-generated from the title and abstract; the full text is not read.
Key points
- FSGLD pipeline integrates generative models (DRUG-GAN) with multiscale simulations and validation for drug lead identification.
- DRUG-GAN can generate random drug-like compounds, target-specific compounds, or series with shared structures.
- FSGLD demonstrated performance in identifying target-specific candidates across three pharmacologically distinct target classes.
- A new TI calculation protocol achieved 80-90% computation time reduction with maintained accuracy.
AI-generated from the title and abstract; the full text is not read.
Abstract
We present the Full-Spectrum Generative Lead Discovery (FSGLD), a deep learning-driven pipeline for efficient drug lead identification. FSGLD integrates generative modeling with molecular docking, molecular dynamics simulations, ligand-residue interaction profile, MM-PBSA, thermodynamic integration (TI), and experimental validation to bridge theoretical design and practical application. The core multiscale DRUG-GAN models enable generative model-guided discovery of drug-like and target-specific compounds across three scenarios: (i) generation of random drug-like compounds, (ii) generation of target-specific compounds, and (iii) generation of target-specific compound series featuring shared chemical structures. In our assessment across three pharmacologically distinct target classes, FSGLD demonstrates encouraging performance in identifying target-specific candidate compounds. In addition, a computational protocol for TI calculations was established to reduce computation time by 80 to 90% while maintaining accuracy. By integrating generative models with in silico and in vitro evaluation techniques, FSGLD reduces the cost of identifying previously uncharacterized yet viable lead compounds, offering remarkable benefits to both academic and industry.
The authors' abstract, as published at the source. Science Advances, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Drug DiscoveryPharmacology, Toxicology and Pharmaceutics